DNMT3A and myelodysplastic syndrome: In this study, we investigate the BM microenvironment in aged controls, CHIP carriers (DNMT3A, TET2), and low-risk MDS patients (DNMT3A, TET2, spliceosome mutations) using multimodal approaches, including targeted RNA profiling, flow cytometry, single-cell sequencing, and imaging.